Atlas Trials

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Clinical trial NCT01499849 · COMPLETED

Trial details

NCT number
NCT01499849
Sponsor
Tesaro, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chemotherapy-induced Nausea and Vomiting
Start date
2012-02-01
Primary completion
2014-05-01
Enrollment
532

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.